Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroOne Medical Technologies Corporation filings document the public-company records of a Nasdaq-listed medical technology issuer developing thin-film electrode and ablation systems for neurological procedures. Current reports and proxy materials disclose operating results, regulatory and clinical update categories, capital-structure actions, governance matters and stockholder voting items.
The company’s SEC record includes Form 8-K disclosures for financial results, Nasdaq listing compliance, certificate amendments, reverse stock split actions, officer and compensation matters, and annual-meeting scheduling. Its definitive proxy statement covers director elections, auditor ratification, equity incentive plan amendments, stockholder proposals and other governance votes tied to NeuroOne’s common stock.
NeuroOne Medical Technologies announced that investors should no longer rely on its interim financial statements for the quarter ended March 31, 2026 because of revenue-recognition errors tied to modified customer purchase orders. The company will amend and restate its Form 10-Q and related disclosures.
The errors caused revenue and accounts receivable to be overstated by an estimated $529,000, gross profit to be overstated by about $296,000, and operating and net loss to be understated by about $296,000. Total assets were overstated by $296,000 and inventory understated by $233,000. The company attributes the issue in part to inadequately designed and implemented internal controls, but states that no intentional misconduct by management or employees was involved.
In the accompanying press release, NeuroOne notes the error reflects a one-time revenue overstatement of approximately $0.5 million against initially reported quarterly revenue of $2.4 million, with no impact on prior periods or cash as of March 31, 2026. The company says ongoing business activities are not affected and reaffirms product revenue guidance of at least $10.5 million for fiscal 2026.
NeuroOne Medical Technologies reported higher product revenue but continued losses and a going concern warning. For the quarter ended March 31, 2026, product revenue was $2.39 million, up from $1.39 million a year earlier, with six‑month product revenue of $5.28 million.
The company posted a quarterly net loss of $2.09 million and a six‑month net loss of $3.52 million, widening from $0.49 million in the prior‑year period. Cash and cash equivalents were $2.8 million, after $4.44 million of operating cash outflows in six months.
Management states there is substantial doubt about NeuroOne’s ability to continue as a going concern beyond its current runway, which it believes extends through September 2026, absent additional capital. A 1‑for‑6 reverse stock split became effective in April 2026, and a March 2026 private placement raised $670,400. Revenue remains highly concentrated in a single customer under the Zimmer distribution relationship.
NeuroOne Medical Technologies reported fiscal second quarter 2026 results for the period ended March 31, 2026. Product revenue reached $2.4 million, up 72% from $1.4 million a year earlier, driven by higher sales of OneRF products, and first-half product revenue grew to $5.3 million from $4.7 million.
Product gross margin in the quarter was 53.8%, with product gross profit of $1.3 million. The company recorded a quarterly net loss of $2.1 million, or $0.25 per basic and diluted share, compared with a $2.3 million net loss in the prior-year quarter.
As of March 31, 2026, NeuroOne held $2.8 million in cash and cash equivalents and $2.4 million in accounts receivable, with working capital of $5.7 million and no debt outstanding. Management highlighted 16 completed OneRF Trigeminal Neuralgia cases with all patients reportedly pain free and ongoing development across brain ablation, drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
NeuroOne Medical Technologies Corporation reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company previously received a deficiency letter on May 6, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days.
On April 30, 2026, Nasdaq notified NeuroOne that the closing bid price of its common stock had been at least $1.00 per share for 10 consecutive business days. As a result, Nasdaq considers the company back in compliance with Nasdaq Listing Rule 5550(a)(2), and the bid price matter is closed.
NeuroOne Medical Technologies announced a planned chief financial officer transition. Ronald McClurg intends to retire as CFO effective June 30, 2026, and will remain with the company as a Senior Advisor until December 31, 2026 to support an orderly handover.
Chief Operating Officer Christopher Volker will become CFO on July 1, 2026. The company highlights his prior senior roles at Abbott, Cardiovascular Systems and St. Jude Medical, as well as investment banking experience in healthcare and technology.
Volker’s base salary will increase to $350,000 with other key employment terms unchanged. NeuroOne and McClurg entered into a Transition and Release Agreement under which he continues current salary and benefits through his Retirement Date in exchange for a general release of claims and customary restrictive covenants.
NeuroOne Medical Technologies Corporation Schedule 13G reports that Brian Pratt and Barbara Pratt each beneficially own 627,344 shares of Common Stock, representing 7.4% of the class. The percentage is computed on 8,420,999 shares outstanding following a 1-for-6 reverse stock split of 50,525,995 shares effective April 15, 2026.
The shares are held in a joint account between each Reporting Person and their spouse; shared voting and dispositive power are reported for each at 627,344 shares. The filing includes a joint filing agreement dated April 21, 2026.
NeuroOne Medical Technologies Corporation is enacting a 1-for-6 reverse stock split of its common stock. Every 6 existing shares will be reclassified into 1 new share, with no change to the total number of authorized shares or the $0.001 par value.
The split becomes effective at 5:00 p.m. Eastern Time on April 15, 2026, and NeuroOne’s stock will begin trading on a split-adjusted basis on April 16, 2026 under the symbol NMTC. Fractional share positions will not be issued; instead, affected stockholders will receive a cash payment equal to the market value of the fractional share. Equity incentive plan awards, options and warrants will be proportionally adjusted, and the company notes the reverse split may help it regain compliance with Nasdaq’s minimum bid price requirement.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jason Richard Mills reported equity compensation awards. He received options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments.
He also received a grant of 41,929 restricted stock units that vest in 12 equal monthly installments over one year, with vesting at the end of each month. Following the stock grant, he holds 49,687 shares of common stock directly.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jeffrey S. Mathiesen received new equity compensation. On April 3, 2026, he was granted options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036. These options vest in 12 equal monthly installments over one year.
On the same date, he also received 41,929 restricted stock units, which vest in 12 equal monthly installments over one year at the end of each month. Following these grants, he directly owns 156,343 shares of common stock. Both grants are compensation awards rather than open-market purchases.
NeuroOne Medical Technologies director Paul Buckman received new equity awards as compensation. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He was also granted 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at the end of each month. Following these awards, he directly holds 178,733 shares of common stock. These are grants, not open-market purchases.